when is retatrutide coming to market 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) showing unprecedented results in Will the FDA approve retatrutide?

It might begin to degrade, losing its potency and leaving your reconstituted peptide vulnerable

As of 2024, retatrutide has not received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) and remains an experimental compound

Our peptide-based metabolic programs are guided by experienced medical professionals within a functional medicine framework for safe and ethical care

Unlike NAD+ precursors, which are often sold as supplements, Sermorelin is a prescription-only medication

Recent studies have pointed to disruptions in various metabolic pathways involved in seizure initiation, propagation, and resistance to ASMs 7,8

That's where GLP-1 supplements come in marketed as a more natural, noninjectable way to tap into similar benefits